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Summary There is emerging evidence to support the unfavorable effects of some
anti-epileptic drugs on the plasma homocysteine concentrations. Elevated homo-
cysteine levels induced by anti-epileptic drug administration can theoretically
increase not only the risk of vascular occlusive diseases, but also the risk of resistance
to anti-epileptics and development of refractory epilepsy. To investigate the effect of
common anti-epileptic drugs on the homocysteine metabolism, a total of 75 epileptic
patients receiving phenytoin (n = 16), carbamazepine (n = 19), or valproic acid
(n = 22) and no anti-epileptic drug (n = 18) were enrolled. Eleven age- and sex-
matched healthy subjects served as the control group. Blood concentrations of
homocysteine, folic acid, Vitamin B12 and pyridoxal 50-phosphate (active circulating
form of Vitamin B6) were measured. Compared to the control group, epileptic
patients on anti-epileptic drug had higher blood levels of homocysteine. No difference
in homocysteine concentrations was observed among epileptic patients in terms of
the anti-epileptic drug used. Patients receiving phenytoin had significantly lower folic
acid levels and those receiving carbamazepine had marginally lower pyridoxal 50-
phosphate levels in comparison with those using other anti-epileptic drugs. A negative
correlation between homocysteine and folic acid concentrations was detected in
epileptic patients on anti-epileptic drug. The duration of anti-epileptic drug use was
correlated to the decrease of folic acid levels, but not with changes observed in
homocysteine, Vitamin B12 and pyridoxal 50-phosphate levels. No relationship
between seizure frequency and homocysteine levels was observed in epileptic
patients. Our results confirm that common anti-epileptic drugs has disadvantageous
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effects on homocysteine status. Because there was no significant change in homo-
cysteine concentrations in epileptic patients who were not receiving an anti-epileptic
drug, and no positive correlation between seizure frequency and homocysteine levels,
we suggest that increase of homocysteine levels may be due to anti-epileptic drug
use, rather than being epileptic in origin. Additionally, the underlying mechanism for
homocysteine increase seems to be a decrease of cofactor molecules in patients using
carbamazepine and phenytoin (pyridoxal 50-phosphate and folic acid, respectively).
However, changes observed are not related to the alteration in the levels of cofactors
and remain unclear in the patients using valproic acid.
# 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Homocysteine is an amino acid formed during the
methionine metabolism. In the cells, almost half of
the homocysteine is used in cysteine synthesis via
transsulfuration by a Vitamin B6 dependent enzyme,
cystathionine beta-synthase. Deficiency of this
enzyme results in homocystinuria, in which homo-
cysteine blood levels are significantly increased.
Major clinical manifestations involve the eyes and
the central nervous, skeletal and vascular systems.
Of note, the incidence of seizures is increased up to
20% in patients with homocystinuria.1 The other half
of the homocysteine is normally remethylated to
methionine, with folic acid, Vitamin B2 and Vitamin
B12 as cofactors. Homocysteine concentrations
increase mildly in the deficiency of these vitamins.
This is a more common form of hyperhomocystei-
nemia, which is a well-established risk factor for
vascular disease via homocysteine associated vas-
cular endothelial damage resulting in acceleration
of atherosclerosis and alterations of the blood coa-
gulation system leading to prothrombotic state.2—4
However, its relation to epilepsy has not been
clearly demonstrated.
Patients on anti-epileptic drugs are prone to high
concentrations of plasma homocysteine and low
status of folate and Vitamin B6.5—7 The conse-
quences of this metabolic disturbance may be of
clinical importance. First, in addition to its adverse
effects on atherogenic lipid levels,8,9 increased
homocysteine levels associated with anti-epileptic
drugs may be a risk factor for systemic vascular
events including stroke. Because the use of the
anti-epileptic drug may be extended over years,
chronic vascular toxicity may be an important con-
cern. Second, increased homocysteine and low
folate status may contribute to the development
of anti-epileptic drug related side effects, such as
impaired cognitive function and fetal malformations
including neural tube defect,10,11 for which hyper-
homocysteinemia is an established independent risk
factor.12,13 Third, and the most speculative,
increased homocysteine may also be involved inpoor seizure control in epileptic patients, based
on the fact that its systemic application is known
to cause an animal model of epilepsy.14
In this study, our main intention was to assess the
effect of monotherapy with common anti-epileptic
drugs on the homocysteine metabolism. We also
attempted to uncover the relationship between
the levels of homocysteine, with the cofactors
involved in its metabolism, and epilepsy control in
addition to other clinically relevant parameters.Patients and methods
Study population
Seventy-five patients with the diagnosis of idio-
pathic generalized epilepsy, followed at the Depart-
ment of Neurology in SSK Tepecik Teaching Hospital,
were studied. The non-anti-epileptic group con-
sisted of 18 patients, including 15 patients with
newly diagnosed epilepsy and 3 patients who had
not been taking any medicine for their epilepsy for
the last 2 years. There were 11 female and 7 male in
this group. Themean age was 30  12 (range 17—45)
years. Fifty-seven patients were receiving anti-epi-
leptic drug monotherapy (anti-epileptic drug group:
carbamazepine (n = 19), valproic acid (n = 22) and
phenytoin (n = 16). Age- and sex-matched 11
healthy volunteers were included into the study
as control group. The mean age of the patients
and controls was 29  11 (range 16—56) and
32  6 (range 25—41) years, respectively. Fourty-
one (55%) of the total patients and 7 (64%) of the
controls were female. The mean duration of treat-
ment of patients receiving anti-epileptic drug was
6.5  6.2 (range 1—26) years. No significant differ-
ence among patients receiving anti-epileptic drug
was observed in terms of age, gender and duration
of treatment ( p > 0.05).
In all patients, serum levels of anti-epileptic
drugs were measured in the same blood samples
obtained for homocysteine, Vitamin B12, pyridoxal
50-phosphate (active circulating form of Vitamin B6)
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serum levels of anti-epileptic drug within the ther-
apeutic range.
Presence of epilepsy due to ischemic stroke,
history of cardiac and peripheral vascular disease,
diabetes mellitus, anemia, pregnancy and renal or
thyroid disease were exclusion criteria. Subjects
using folic acid antagonists and vitamins, as well as
vegetarians were also excluded. Patients with
silent brain infarction on magnetic resonance ima-
ging were excluded, as well. Seizure frequency
was calculated by dividing the total number of
seizures to the duration of disease. The duration
of epilepsy in untreated patients was shorter than
those in the treated patients (6  8 years versus
11  8 years).
Biochemical analysis
Following an overnight fasting period, blood sam-
ples were obtained between 8 and 10 a.m. before
receiving the morning dose of the anti-epileptic
drug. Venous blood was taken from the antecubital
vein in the sitting position. Serum was immediately
separated by centrifugation after discharging. The
supernatant was removed and stored at20 8C until
assayed.
Serum homocysteine, Vitamin B12 and folic acid
concentrations were measured by immunoassay
method using commercial kits (Immulite1, DPC,
United States). Reference values for the kits were
5—12 mmol/L for homocysteine, 3—17 ng/mL for
folic acid and 100—700 pg/mL for Vitamin B12.
The values above the 12 mmol/L were accepted
as hyperhomocysteinemia. Pyridoxal 50-phosphate
concentrations were measured by high perfor-
mance liquid chromatography (HPLC; Millipore1;
Waters 625 LC system, United States) using com-
mercial kits purchased from Chromsystems Diag-
nostics (Germany). The flurometer was set at
370 nm excitation with emission monitored at
470 nm. Flow rate was adjusted, as 1.3 mL/min.
Reference values were 3.6—18 ng/mL. Anti-epi-
leptic drug serum concentrations were deter-
mined by enzyme multiplied immunochemical
technique.
Statistical analysis
Distribution of every variable was assessed using the
Kolmogorov—Smirnov’s test. Analyses of parametric
variables were performed using one-way variance
analysis (ANOVA) with post hoc Benferroni’s test. In
analyses of non-parametric variables, Kruskal—
Wallis test with post hoc Mann—Whitney U-test
was used. Furthermore, a multivariate analysis withgeneral linear modelling was performed to adjust
the effects of age and sex on the parameters stu-
died. For this method, both of ‘‘F’’ and ‘‘p’’ values
were reported in the results. In correlation of homo-
cysteine with the other variables, Pearson’s and
Spearman’s correlation tests were used in each
group as appropriate. Numerical data were shown
as ‘‘mean  standard deviation (S.D.)’’. Statistical
significance level was set at p < 0.05. For multiple
comparisons, significance level was defined as
p < 0.05/‘‘number of comparisons’’.Results
Hemoglobin and hemotocrit levels, renal and liver
function tests were in normal limits in all groups. Of
note, serum creatinine concentrations were normal,
and did not show any correlation to the parameters
(data not shown).
Homocysteine
In all groups, homocysteine levels were between 2.6
and 44.7 mmol/L except one patient using carba-
mazepine. In this patient, homocysteine level was
measured as 100 mmol/L.
The percentage of subjects with hyperhomocys-
teinemia, defined as homocysteine concentration
more than 12 mmol/L, was significantly higher in
the anti-epileptic drug group (64%) in comparison
with non-anti-epileptic drug and control groups
(20%) and (27%), respectively.
Mean homocysteine level was higher in anti-epi-
leptic drug group than in non-anti-epileptic drug and
control groups (p < 0.05) (Table 1). This significant
difference was found across all anti-epileptic sub-
groups, namely valproic acid, carbamazepine and
phenytoin users, when compared to the values
obtained in non-anti-epileptic drug groups. There
was no significant difference among the anti-epi-
leptic drug subgroups, when compared to each
other.
After adjustment of age and sex with multivari-
ate modelling, the significance of the differences
persisted. In detail, with this statistical methodol-
ogy, significantly higher homocysteine levels were
again found in patients using any anti-epileptic
medications (F = 7.378, p < 0.05); in those using
carbamazepine (F = 7.39, p < 0.05), valproic acid
(F = 9.745, p < 0.05) and phenytoin (F = 9.745,
p < 0.05).
No difference was observed between mean
homocysteine concentrations measured in the
non-anti-epileptic drug group and controls.
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Table 1 Level of homocysteine and co-factors in groups
Groups Homocysteine Folic acid Pyridoxal 50-phosphate Vitamin B12
Anti-epileptic
drug group (n = 57)
17.9  14.1
(3.4—100)
5.5  3.0
(1.2—15.0)
3.3  2.3
(0.8—12.0)
360  174
(139—869)
Carbamazepine
(n = 19)
19.6  21.4
(3.4—100)
5.4  3.4
(1.4—15.0)
2.8  2.1
(0.9—8.0)
270  98
(144—473)
Valproic acid (n = 22) 17.0  8.0
(8.5—38.6)
6.8  3.0
(2.0—13.9)
3.2  2.0
(0.8—7.9)
441  174
(139—869)
Phenytoin (n = 16) 17.2  9.2
(8.2—36.6)
4.1  1.6
(1.2—6.7)
4.0  2.7
(1.1—12.0)
349  194
(157—766)
Non-anti-epileptic
drug group (n = 18)
9.8  5.9
(2.6—22.6)
6.4  2.8
(2.6—12.4)
5.5  4.5
(2.6—16.0)
338  186
(158—895)
Controls (n = 11) 11.5  11.4
(4.6—44.7)
8.8  3.6
(2.9—16.1)
4.7  3.4
(1.6—11.6)
315  136
(184—621)
Numbers indicate mean  S.D. Range
(minimum—maximum) is shown in brackets.Folic acid
After adjustment for age and sex, patients on anti-
epileptic drugs had significantly lower folic acid
levels compared to the control group (F = 4.817,
p < 0.05). Considering the anti-epileptic medica-
tion subgroups, folic acid levels differed only in
patients using phenytoin (F = 11.8, p < 0.05) and
were found not to be different in valproic acid
(F = 1.38, not significant (NS)) and carbamazepine
users (F = 0.902, NS). There was no difference in
folic acid levels among non-anti-epileptic drug and
control groups.
Vitamin B6 (pyridoxal 50-phosphate)
Mean pyridoxal 50-phosphate level was lower in anti-
epileptic drug group than those in non-anti-epileptic
drug group and the control ones. Unfortunately, after
adjustment for age and sex, the observed differences
on univariate analyses did not persist. The only dif-
ference was that the patients taking carbamazepineFigure 1 Correlation between homocysteine and folic acid c
users.showed a tendency for decreased level of pyridoxal
50-phosphate (F = 0.597, p = 0.062).
Vitamin B12
No difference was found among the entire study
population ( p = 0.701, p = 0.357), or in anti-epilep-
tic drug subgroup compared to the controls on uni-
and multivariate analyses.
Association of homocysteine with folic
acid, pyridoxal 50-phosphate and Vitamin
B12
A significant negative correlation was found
between the levels of homocysteine and folic acid
(r = 0.332, p < 0.05) in patients using anti-epi-
leptic drugs and in entire study population
(r = 0.410, p < 0.05) (Fig. 1). No association
was found between homocysteine and pyridoxal
50-phosphate as well as homocysteine and Vitamin
B12.oncentrations. (A) Entire population and (B) anti-epileptic
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folic acid, pyridoxal 50-phosphate and
Vitamin B12 with the duration of
treatment and disease
There was a negative correlation between the dura-
tion of treatment and folic acid levels in the anti-
epileptic drug group (r = 0.27, p = 0.045). No cor-
relation was found between the levels of homocys-
teine, pyridoxal 50-phosphate, Vitamin B12 and the
duration of treatment and the disease ( p > 0.05).
Relationship between seizure frequency
and the level of homocysteine
There was no significant association between the
seizure frequency and the level of homocysteine.
Also, there was no difference in homocysteine con-
centrations between patients who remained seizure
free and the patients who had at least one seizure
during the last year or the last 3 months.Discussion
The relationship between increased homocysteine
level and epileptic seizure remains controversial in
humans despite a growing evidence of the pro-con-
vulsive effect of the hyperhomocysteinemia
observed in the animal studies. The mechanism of
this association with epileptogenesis has not been
clearly understood, but some evidence is available.
Homocysteine and its oxidative product, homocys-
teic acid, are potent agonists of the N-methyl-D-
aspartate (NMDA)-type glutamate receptor, which
are linked with epileptogenesis.15 Furthermore,
there is somedata fromanimal studiesdemonstrating
that homocysteine sequesters adenosine, an endo-
genous anti-convulsant and thereby reduces the sei-
zure threshold.16 Additionally, up to 20% of patients
with homocystinuria have seizures1 and high plasma
concentrations of homocysteine (50—200 mmol/L)
have been reported in these patients.17 And, Ono
et al.18 also reported that seizures could not be
controlled optimally when the homocysteine level
is above 20 mmol/L. These data suggest that
increased homocysteine levels may be related to
epileptogenesis and/or sub-optimal control of sei-
zures in thepatientswithepilepsy.We tried toanswer
this question by including untreated epilepsy
patients (the non-anti-epileptic drug group) into
the study and by correlating seizure frequency to
homocysteine levels in theepilepticpatients studied.
As a result, no difference was observed between the
measured mean homocysteine concentrations ofnon-anti-epileptic drug and control groups. Also,
no positive correlation of increased homocysteine
levels to seizure frequency was detected in epileptic
patients. These observations support the hypothesis
of Ono et al.18 that a milder increase, less than
20 mmol/L, in homocysteine levels may not be unfa-
vorable in seizure control. At this point, our study
provides more reliable data, because, unlike non-
homogeneity of patients studied by Ono et al.18 in
terms of epilepsy etiology and anti-epileptic drugs
used, our study population is quite homogenous (all
were with idiopathic epilepsy and were receiving
monotherapy).
Data regarding anti-epileptic drugs and their
effect on homocysteine metabolism have been con-
troversial. Schwaninger et al.5 and Ono et al.18,19
reported that anti-epileptic drugs elevated homo-
cysteine concentrations in patients on polytherapy.
However, no strict agreement is available on
patients receiving monotherapy. Some studies
reported elevated homocysteine levels with carba-
mazepine6,7,20,21 and valproic acid6,7,21 use. How-
ever, others reported no changes in homocysteine
levels with carbamazepine5 and valproic acid.22 Our
study results are in agreement with the previous
reports which have found high homocysteine con-
centrations in patients receiving monotherapy.
Furthermore, our data showed that a significant
proportion (almost half) of the epileptic patients
taking anti-epileptic drug have abnormally
increased homocysteine levels. Because we studied
both epileptic patients not receiving anti-epileptic
drugs and healthy controls, and demonstrated that
there were no differences in homocysteine levels
between them, we think that we have successfully
excluded the effects of being epileptic on homo-
cysteine status which has not been considered in
most of the studies. For this reason, we suggest that
the drugs, rather than the disease, play a major role
in the development of hyperhomocysteinemia in
epileptic patients.
Little is known about how phenytoin, carbama-
zepine and valproic acid exert their effects on
homocysteine metabolism. It has been suggested
that phenytoin and carbamazepine, as enzyme indu-
cers, can directly modulate the activity of different
liver enzymes.23 Liver enzyme induction may cause
depletion of the cofactor involved, folic acid, pyr-
idoxal 50-phosphate and Vitamin B12, leading to the
alterations observed in homocysteine status. It is
well-known that patients on phenytoin often have
low serum folic acid levels. Data from several inves-
tigations showed that valproic acid is associated
with either low6,7 or normal22 folic acid levels. Some
studies also revealed that carbamazepine use was
associated with low folic acid status.6,7,20 In our
84 U. Sener et al.study, the patients receiving phenytoin had lower
folic acid levels in comparison to the control groups.
The data regarding Vitamin B12 status after anti-
epileptic drug use is also conflicting. Studies showed
decreased21 and normal5—7 Vitamin B12 levels in
epileptic patients using carbamazepine, and nor-
mal7,21 or increased6 Vitamin B12 levels associated
with valproic acid use. In our study, there was no
difference in Vitamin B12 levels of the anti-epileptic
drug, non-anti-epileptic drug and control groups. In
association with use of valproic acid and carbama-
zepine, pyridoxal 50-phosphate levels have been
reported to be decreased in most of the studies
on record.5—7 Our results are somewhat supportive
of this association with carbamazepine. Even though
no changes in gamma-glutamyl transferase concen-
trations as a sign of enzyme induction were
observed, we still consider that hyperhomocystei-
nemia can be secondary to reduced cofactor levels
(folic acid and possibly pyridoxal 50-phosphate levels
in the patients receiving phenytoin and carbamaze-
pine, respectively). Evidently, valproic acid does not
have a similar effect on liver enzymes. It is probably
for this reason that our patients, receiving valproic
acid, did not have reduced levels of cofactors. This
observation indicates that in valproic acid treated
patients another mechanism, unrelated to cofac-
tors, may take role in the development of hyperho-
mocysteinemia.
It has been shown that blood concentration of
folic acid is inversely related to the blood concen-
tration of homocysteine. On the other hand, the
relationship of homocysteine levels to pyridoxal 50-
phosphate and Vitamin B12 status is not clear.24,25 In
our study, a negative correlation was only found
between folic acid and homocysteine levels. The
level of folic acid was negatively correlated with
duration of treatment. However, we did not find any
correlation between the duration of treatment and
the levels of homocysteine. This is in accordance
with some,26 but not all studies.6,19
In conclusion, hyperhomocysteinemia is much
more prevalent in the patients using anti-epileptic
drugs. It has been reported that increased homo-
cysteine level can be lowered with supplementation
of its cofactors, folic acid, Vitamin B12 and Vitamin
B6.27 Supplementation is inexpensive, effective and
devoid of adverse effects and, therefore, has an
exceptionally favorable benefit/risk ratio. Reduc-
tion of elevated plasma homocysteine concentra-
tions to less than 10 mmol/L may theoretically
prevent up to 25% of cardiovascular events. Until
the results of ongoing randomized controlled trials
become available for beneficial effect of screening
and treatment of hyperhomocysteinemia, recom-
mendation for the apparently healthy general popu-lation may not be advisable. However, because of
the high frequency in patients receiving anti-epi-
leptic drug therapy, we suggest that homocysteine
levels should be routinely screened in all, and be
treated when its level is found to be high. This
approach may be more relevant particularly in some
epileptic patient groups, such as pregnant epileptic
patients because of a possible relation with neural
tube defect.
References
1. Mudd SH, Skovby F, Levy HL, et al. The natural history of
homocystinuria due to cystathionine beta-synthase defi-
ciency. Am J Human Genet 1985;37:1—31.
2. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quan-
titative assessment of plasma homocysteine as a risk factor
for vascular disease. Probable benefits of increasing folic acid
intakes. J Am Med Assoc 1995;274:1049—57.
3. den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteine-
mia as a risk factor for deep-vein thrombosis. New Engl J Med
1996;334:759—62.
4. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine
as a risk factor for vascular disease. J Am Med Assoc
1997;277:1775—81.
5. Schwaninger M, Ringleb P, Winter R, et al. Elevated plasma
concentrations of homocysteine in antiepileptic drug treat-
ment. Epilepsia 1999;40:345—50.
6. Vilaseca MA, Monros E, Arthuch R, et al. Anti-epileptic drug
treatment in children: hyperhomocysteinemia. B-vitamins
and the 677C! T mutation of the methylenetetrahydrofo-
late reductase gene. Eur J Paediatr Neurol 2000;4:269—77.
7. Verrotti A, Pasceralla R, Trotta D, Giuva T, Morgese G,
Chiarelli F. Hyperhomocysteinemia in children treated with
sodium valproate and carbamazepine. Epilepsy Res
2000;41:253—7.
8. Bramswing S, Kerksiek A, Sudhop T, Luers C, Bergman KV,
Berthold HK. Carbamazepine increases atherogenic lipopro-
teins: mechanism of action in male adults. Heart Circ Physiol
2002;282:704—16.
9. Tumer L, Serdaroglu A, Hasanoglu A, Biberoglu G, Aksoy E.
Plasma homocysteine and lipoprotein (a) levels as risk
factors for atherosclerotic vascular disease in epileptic
children taking anticonvulsants. Acta Paediatr 2002;91:
923—6.
10. Arpino C, Brescianini S, Robert E, et al. Tetatogenic effects of
antiepileptic drugs: use of an International Database on
Malformations and Drug Exposure (MADRE). Epilepsia
2000;41:1436—43.
11. Loring DW, Meador KJ. Cognitive side effects of antiepileptic
drugs in children. Neurology 2004;62:872—7.
12. Vollset SE, Refsum H, Irgens LM, et al. Plasma total homo-
cysteine, pregnancy complications, and adverse pregnancy
outcomes: the Hordaland Homocysteine Study. Am J Clin
Nutr 2000;71:962—8.
13. Prins ND, den Heijer T, Hofman A, et al. Homocysteine and
cognitive function in the elderly. Neurology 2002;59:1375—
80.
14. Kubova H, Folbergrova J, Mares P. Seizures induced by homo-
cysteine in rats during ontogenesis. Epilepsia 1995;36:
750—6.
15. Lipton SA, Kim WK, Choi YB, et al. Neurotoxicity associated
with dual actions of homocysteine at the N-methyl-D-aspar-
tate receptor. Proc Natl Acad Sci USA 1997;94:5923—8.
Effects of anti-epileptic drugs on homocysteine 8516. Marangos PJ, Loftus T, Weisner J, et al. Adenosinergic mod-
ulation of homocysteine-induced seizures in mice. Epilepsia
1990;31:239—46.
17. Schwarz S, Zhou GZ. N-methyl-D-aspartate receptors and
CNS symptoms of homocystinuria. Lancet 1991;337:
1226—7.
18. Ono H, Sakamoto A, Mizoguchi N, Sakura N. The C677T
mutation in the methylenetetrahydrofolate reductase gene
contributes to hyperhomocysteinemia in patients taking
anticonvulsants. Brain Dev 2002;24:223—6.
19. Ono H, Sakamoto A, Eguchi T, et al. Plasma total homocys-
teine concentrations in epileptic patients taking anticonvul-
sants. Metabolism 1997;46:959—62.
20. Apeland T, Mansoor MA, Strandjord RE, Vefring H, Kristensen
O. Folate, homocysteine and methionine loading in
patients on carbamazepine. Acta Neurol Scand 2001;103:
294—9.
21. Karabiber H, Sonmezgoz E, Ozerol E, Yakinci C, Otlu B,
Yologlu S. Effects of valproate and carbamazepine on serum
levels of homocysteine, Vitamin B12, and folic acid. Brain
Dev 2003;25:113—5.22. Apeland T, Mansoor MA, Strandjord RE. Antiepileptic drugs as
independent predictors of plasma total homocysteine levels.
Epilepsy Res 2001;47:27—35.
23. Kishi T, Fujita N, Eguchi T, Ueda K. Mechanism for reduction of
serum folate by antiepileptic drugs during prolonged therapy.
J Neurol Sci 1997;145:109—12.
24. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH.
Vitamin status and intake as primary determinants of homo-
cysteinemia in an elderly population. J Am Med Assoc
1993;270:2693—8.
25. Lee BJ, Lin PT, Liaw YP, Chang SJ, Cheng CH, Huang YC.
Homocysteine and risk of coronary artery disease: folate is
the important determinant of plasma homocysteine concen-
tration. Nutrition 2003;19:577—83.
26. Yoo JH, Hong SB. A common mutation in the methylenetetra-
hydrofolate reductase gene is a determinant of hyperhomo-
cysteinemia in epileptic patients receiving anticonvulsants.
Metabolism 1999;48:1047—51.
27. Apeland T, Mansoor MA, Pentieva K, McNulty H, Seljeflot I,
Strandjord RE. The effect of B-vitamins on hyperhomocys-
teinemia in patients on antiepileptic drugs. Epilepsy Res
2002;51:237—47.
